We are live on ! Find out more
ITCI

Intra-Cellular Therapies Inc.
ITCI

Delisted

ITCI was delisted on the 1st of April, 2025.

Back to rankings

131 hedge funds and large institutions have $829M invested in Intra-Cellular Therapies Inc. in 2018 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 41 increasing their positions, 47 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more capital invested

Capital invested by funds: $553M → $829M (+$276M)

47% more call options, than puts

Call options by funds: $30.8M | Put options by funds: $21M

5% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 19

0% more funds holding

Funds holding: 131 → 131 (0)

13% less repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 47

Holders
131
Holders Change
–
Holders Change %
0%
% of All Funds
3%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
20
Increased
41
Reduced
47
Closed
19
Calls
$30.8M
Puts
$21M
Net Calls
+$9.81M
Net Calls Change
+$5.83M

Top Buyers

1
PC
PointState Capital
New York
+$36.4M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$21.8M
3
Citadel Advisors
Citadel Advisors
Florida
+$18.9M
4
DFO
Duquesne Family Office
New York
+$5.79M
5
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$5.69M

Top Sellers

1
Millennium Management
Millennium Management
New York
-$17.2M
2
BBA
Baker Bros. Advisors
New York
-$8.82M
3
SC
Samlyn Capital
New York
-$6.83M
4
RPAM
Rhenman & Partners Asset Management
Sweden
-$5.69M
5
BlackRock
BlackRock
New York
-$4.87M
Name Holding Trade Value Shares
Change 		Change in
Stake
PAM
26
Panagora Asset Management
Massachusetts
$5.08M +$724K +37,189 +18%
Point72 Asset Management
27
Point72 Asset Management
Connecticut
$4.85M -$4.28M -219,506 -49%
Charles Schwab
28
Charles Schwab
California
$4.8M +$124K +6,357 +3%
D.E. Shaw & Co
29
D.E. Shaw & Co
New York
$4.68M +$3.59M +184,416 +483%
TCIM
30
TIAA CREF Investment Management
New York
$4.62M +$878K +45,053 +26%
CS
31
Candriam SCA
Luxembourg
$4.59M -$1.21M -62,000 -22%
Man Group
32
Man Group
United Kingdom
$4.56M +$4.22M +216,759 New
Bank of New York Mellon
33
Bank of New York Mellon
New York
$4.39M -$122K -6,270 -3%
DekaBank Deutsche Girozentrale
34
DekaBank Deutsche Girozentrale
Germany
$4.39M -$1.48M -76,000 -26%
RSCM
35
Rock Springs Capital Management
Maryland
$3.95M – – –
Susquehanna International Group
36
Susquehanna International Group
Pennsylvania
$3.19M +$912K +46,818 +45%
CWG
37
C WorldWide Group
Denmark
$2.89M -$1.66M -85,107 -38%
PP
38
PDT Partners
New York
$2.44M -$356K -18,254 -14%
FMBTD
39
First Midwest Bank Trust Division
Illinois
$2.23M -$1.58M -80,938 -43%
Two Sigma Investments
40
Two Sigma Investments
New York
$2.03M -$1.18M -60,800 -39%
WMSA
41
Weiss Multi-Strategy Advisers
New York
$2M -$195K -10,000 -10%
HSBC Holdings
42
HSBC Holdings
United Kingdom
$2M +$1.85M +94,808 New
BG
43
Bellevue Group
Switzerland
$1.92M -$29.2K -1,500 -2%
Federated Hermes
44
Federated Hermes
Pennsylvania
$1.89M -$1.3M -66,842 -43%
Ohio Public Employees Retirement System (OPERS)
45
Ohio Public Employees Retirement System (OPERS)
Ohio
$1.75M +$271K +13,931 +20%
TA
46
Teachers Advisors
New York
$1.65M -$4.52K -232 -0.3%
Group One Trading
47
Group One Trading
Illinois
$1.57M +$321K +16,499 +28%
Swiss National Bank
48
Swiss National Bank
Switzerland
$1.56M +$87.7K +4,500 +6%
PA
49
Perceptive Advisors
New York
$1.47M +$1.36M +70,000 New
PAMU
50
Pictet Asset Management (UK)
United Kingdom
$1.46M +$1.35M +69,500 New
1
2
3 4 5

ITCI Hedge Fund Activity: Q1 2018 in Review

131 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q1 2018, worth a combined $829M — up 50% from $553M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new ITCI positions and 19 closed out — a net gain of 1 holder — while 41 added to existing stakes and 47 trimmed.

The largest buyer was PointState Capital, opening a new position worth an estimated $36.4M. The largest seller was Millennium Management, cutting an estimated $17.2M.

  • 131 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q1 2018, unchanged from Q4 2017.
  • Funds reported $829M of Intra-Cellular Therapies Inc. stock for Q1 2018, up 50% quarter-over-quarter.
  • 20 funds opened new Intra-Cellular Therapies Inc. positions in Q1 2018 and 19 closed out, a net change of +1 holder.
  • The largest Intra-Cellular Therapies Inc. buyer in Q1 2018 was PointState Capital, an estimated $36.4M added.
  • The largest Intra-Cellular Therapies Inc. seller in Q1 2018 was Millennium Management, an estimated $17.2M sold.

Based on aggregated 13F filings for Q1 2018.